Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-07-18
2006-07-18
Minnifield, Nita (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S234100, C424S237100, C424S139100, C424S130100, C424S150100, C424S165100, C530S300000, C530S324000, C530S350000, C530S387100, C514S002600, C514S008100
Reexamination Certificate
active
07078042
ABSTRACT:
Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or “PspC”, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or ofS. pneumoniaeby detecting a nucleic acid molecule therefor in a sample such as by amplification and/or a polymerase chain reaction, vectors or plasmids which contain and/or express such nucleic acid molecles, e.g., in vitro or in vivo, immunological, immunogenic or vaccine compositions including at least one PspC and/or a portion thereof (such as at least one epitopic region of at least one PspC and/or at least one polypeptide encoding at least one epitope of at least one PspC), either alone or in further combination with at least one second pneumococcal antigen, such as at least one different PspC and/or a fragment thereof and/or at least one PspA and/or at least one epitopic region of at least one PspA and/or at least one polypeptide including at least one epitope of PspA. PspC or a fragment thereof, and thus a composition including PspC or a fragment thereof, can be administered by the same routes, and in approximately the same amounts, as PspA. Thus, the invention further provides methods for administering PspC or a fragment thereof, as well as uses of PspC or a fragment thereof to formulate such compositions.
REFERENCES:
patent: 5476929 (1995-12-01), Briles et al.
patent: 5679768 (1997-10-01), Briles et al.
patent: 5728387 (1998-03-01), Briles et al.
patent: 5753463 (1998-05-01), Briles et al.
patent: 5804193 (1998-09-01), Briles et al.
patent: 5856170 (1999-01-01), Briles et al.
patent: 5871943 (1999-02-01), Briles et al.
patent: 5955089 (1999-09-01), Briles et al.
patent: 5965141 (1999-10-01), Briles et al.
patent: 5980909 (1999-11-01), Briles et al.
patent: 6004802 (1999-12-01), Briles et al.
patent: 6027734 (2000-02-01), Briles et al.
patent: 6042838 (2000-03-01), Briles et al.
patent: 6231870 (2001-05-01), Briles et al.
patent: 6232116 (2001-05-01), Briles et al.
patent: 6245335 (2001-06-01), Masure et al.
patent: 6291654 (2001-09-01), Hostetter et al.
patent: 6420135 (2002-07-01), Kunsch et al.
patent: 6500613 (2002-12-01), Briles et al.
patent: 6503511 (2003-01-01), Wizemann et al.
patent: 6573082 (2003-06-01), Choi et al.
patent: 6592876 (2003-07-01), Briles et al.
patent: 6638516 (2003-10-01), Becker et al.
patent: 6784164 (2004-08-01), Masure et al.
patent: 6943241 (2005-09-01), Isogai et al.
patent: 2001/0016200 (2001-08-01), Briles et al.
patent: 2002/0061545 (2002-05-01), Choi et al.
patent: 2003/0059438 (2003-03-01), Briles et al.
patent: 2003/0091577 (2003-05-01), Gilbert et al.
patent: 2003/0096950 (2003-05-01), Tuomanen et al.
patent: 2004/0067237 (2004-04-01), Becker et al.
patent: 2004/0077847 (2004-04-01), Briles et al.
patent: 2004/0081662 (2004-04-01), Hermand et al.
patent: 2004/0241638 (2004-12-01), Thonnard
patent: 2004/0241687 (2004-12-01), Thonnard et al.
patent: 2005/0031646 (2005-02-01), Capiau et al.
patent: 2005/0118659 (2005-06-01), Castado et al.
patent: 2005/0196405 (2005-09-01), Briles et al.
patent: 2104014 (1992-08-01), None
patent: 2116261 (1994-10-01), None
patent: 2149345 (1995-11-01), None
patent: 2232033 (1997-03-01), None
patent: 2253252 (1997-11-01), None
patent: 0 622 081 (1994-11-01), None
patent: 0 695 803 (1996-02-01), None
patent: 1 477 185 (2004-11-01), None
patent: WO 92/14488 (1992-09-01), None
patent: WO 93/24000 (1993-12-01), None
patent: WO 97/09994 (1997-03-01), None
patent: WO 98/21337 (1998-05-01), None
patent: WO 99/53940 (1999-10-01), None
patent: WO 00/56359 (2000-09-01), None
patent: WO 00/76541 (2000-12-01), None
patent: WO 02/084426 (2002-01-01), None
Briles, “PspA's Affect on Lactoferrin Killing of Pneumococci,” National Institute of Health/National Institute of Allergy and Infectious Diseases Grant No. 1 RO1 A10610 38-01, pp. 2 (2003).
Beall et al J. Clin. Microbiol, 38/10: 3663-3669, 2000.
Talkington et al, Infection & Immunity, 59/4: 1285-1289, 1991.
Kuroki et al, J. Biol. Chem. 263/7: 3388-3394, 1988.
Kolberg et al FEMS Immunol & Med. Microb. 29: 289-294, 2000.
McDaniel et al Microbial Pathogenesis 17:323-337, 1994.
Briles et al, Vaccine 18: 1707-1711, 2000.
Nabors et al, Vaccine 18: 1743-1754, 2000.
Brooks-Walter et al, Infection & Immunity 67/12 :6533-6542, 1999.
Hollingshead et al, Infection & Immunity 68/10: 5889-5900, 2000.
HåKansson et al Infection & Immunity 69/5: 3372-3381, 2001.
Crain et al Microbial Pathogenesis 21:265-275, 1996.
Dave et al Infection & Immunity 69/5:3435-3437, 2001.
Ralph et al Annals. NY. Acad. Sciences.
Brooks-Walter ASM Annual Mtg 1997 (Abstract only) p. 35 Abstract #B-37.
Swiatlo et al, Gene, 188: 279-284, 1997.
Briles et al, Microbial Drug Resistance 3/4:401-408, 1997.
Hammerschmidt et al., “SpsA, A NovelPneumococcalSurface Protein With Specific Binding to Secretory Immunoglobin A and Secretory Component, Molecular Immunology”, vol. 25, pp. 1113-1124, 1997.
Tomasz, A., “Choline in the Cell Wall of a Bacterium: Nove1 Type of Polymer-Linked Choline inPneumococcus”, Science, vol. 157, pp. 694-697, 1967.
Briese et al., “Interactions of the Pneumococcal Amidase with Lipoteichoic Acid and Choline”, Eur. J. Biochem., vol. 146, pp. 417-427, 1985.
Sanchez-Beato et al., “Molecular Characterization of a Family of Choline-Binding Proteins ofClostridium beijerinckiiNCIB 8052. Evolution and Gene Redundancy in Prokaryotic Cell”, Gene, vol. 180, pp. 13-21, 1996.
Sanchez-Beato et al., Molecular Characterization of PcpA: A Novel Choline-Binding ofStreptococcus pneumoniae, FEMS Microbiology Letters 164, pp. 207-214, 1997.
Banas et al., “Sequence Analysis of the Gene for the Glucan-Binding Protein ofStreptococcus mutansIngritt”, Infection and Immunity, vol. 58, No. 3, pp. 337-673, 1990.
Briles et al., “PspA and PspC: Their Potential for Use asPneumococcalVaccines”, Microbial Drug Resistance, vol. 3, No. 4, pp. 401-408, 1997.
Briles et al., “PspA, a Protection-Eliciting Pneumococcal Protein: Immunogenicity of Isolated Native PspA in Mice”, Vaccine, vol. 14, No. 9, pp. 858-867, 1996.
McDaniel et al., Use of Insertional Inactivation to Facilitate Studies of Biological Properties of Pneumococcal Surface Protein A (PspA), J. Exp. Med., vol. 165, pp. 381-394, Feb. 1987.
McDaniel et al., “PspA, A Surface Protein ofStreptococcus pneumoniae,Is Capable of Eliciting Protection Against Pneumococci of More Than One Capsular Type”, Infection and Immunity, pp. 222-228, Jan. 1991.
McDaniel et al., “Molecular Localization of Variable and Conserved Regions of pspA and Identification of Additional pspA Homologous Sequences inStreptococcus pneumoniae”, Microbial Pathogenesis, pp. 261-269, 1992.
McDaniel et al., “Localization of Protection-Eliciting Epitopes on PspA ofStreptococcus pneumoniaeBetween Amino Acid Residues 192 and 260”, Microbial Pathogenesis, pp. 323-327, 1994.
McDaniel et al., “Monoclonal Antibodies Against Surface Component ofStreptococcus pneumoniae”, Monoclonal Antibodies Against Antibodies, vol. III, pp. 143-164.
McDaniel et al., “Immunization with a Plasmid Expressing Pneumococcal Surface Protein A (PspA) Can Elicit Protection Against Fatal Infection withStreptococcus pneumoniae”, Gene Therapy, vol. 4, pp. 375-377, 1997.
McDaniel et al., “Analysis of a Surface Protein ofStreptococcus pneumoniaeRecognized by Protective Monoclonal Antibodies”, Microbial Pathogenesis, vol. 1, ppp. 519-531, 1986.
McDaniel et al., “Comparison of the PspA Sequence fromStreptococcus pneumoniaeEF5668 to the Previously Identified PspA Sequence from Strain Rx1 and Ability of PspA from EF5668 to Elicit Protection againstPneumococciof Different Capsular Types”, Infection and Immunity, vol. 66, No. 10, pp. 4748-4
Briles David E.
Brooks-Walter Alexis
Hollingshead Susan K.
Minnifield Nita
Nixon & Peabody LLP
UAB Research Foundation
LandOfFree
Pneumococcal surface protein C (PspC), epitopic regions and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pneumococcal surface protein C (PspC), epitopic regions and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pneumococcal surface protein C (PspC), epitopic regions and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3586220